Home » Archive

Articles tagged with: ErbB2

Basic Research »

[30 May 2012 | No Comment | 11,049 views]
Perifosine: novel treatment for mesothelioma?

The PI3K/AKT signaling pathway is aberrantly active and may have an important biologic impact in malignant pleural mesothelioma cell cycle progression and chemo-resistance. Moreover, the EGFR family, EGFR, ErbB2 or ErbB3, is frequently co-activated with MET, suggesting that MET and EGFR may compensate for each other in activating downstream signals. Perhaps because of these multiple active pathways, single receptor tyrosine kinase (RTK) inhibitors are generally not sufficient to inhibit mesothelioma cell proliferation and inhibition of multiple RTKs may be needed for a more effective therapy.